Ascentage Pharma Group International (AAPG): Koefisien rega marang pendapatan
The prospects of Ascentage Pharma Group (AAPG) depend on the international recognition of olverembatinib and expansion into the US. Historical P/S dynamics confirm market expectations, where the current parameter equals 8.50. Growth is based on the global promotion of targeted drugs and alliances with big pharma. A positive forecast is supported by the development of apoptosis inhibitors aimed at combating tumor resistance within the framework of innovative R&D.
Ascentage (AAPG) - rincian metrik lan laporan keuangan
- nilai saham lan prakiraan konsensus rega:
- data kapitalisasi bursa:
- rincian nilai buku perusahaan:
- statistik kawajiban utang lan likuiditas:
Rasio Utang marang Ekuitas Ascentage Pharma Group|AAPG - Rasio utang jangka dawa marang ekuitas|Rasio silihan jangka cendhak marang modal Ascentage Pharma Corp|AAPG - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Ascentage|AAPG - Utang jangka dawa perusahaan|Tanggungan jangka cendhak Ascentage Pharma|Likuiditas darurat ascentage.com
- data bathi bisnis lan rasio investasi:
AAPG - Penghasilan resik|Penghasilan resik sing dikarepake Ascentage Pharma Group|AAPG - Rasio rega marang bathi|Rasio rega marang bathi sing dikarepake Ascentage Pharma Group International|AAPG - Pangali PEG|Nilai bisnis marang bathi operasional sadurunge panyusutan Ascentage|AAPG - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Ascentage Pharma|AAPG - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan ascentage.com|AAPG - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Ascentage Pharma Group
- rincian pendapatan lan dodolan emiten:
Analisis umum perusahaan:AAPG ascentage.com
To isolate fundamental stability from market noise, the ratio of market capitalization to annual sales is utilized, allowing for the valuation of each unit of revenue without accounting distortions. Analyzing the price-to-sales multiple helps align current investor expectations with the commercialization potential of olverembatinib and the expansion prospects of Ascentage Pharma Group (AAPG) into the US market.
Perusahaan pesaing
Multiplikator P/S beigene.com (ONC)|Rasio rega marang pendapatan Halozyme HALO|Koefisien rega marang pendapatan Revolution Medicines Inc (RVMD)|CG Oncology Corp - Multiplikator P/S|UroGen Pharma Corp (URGN) - Kapitalisasi marang pendapatan|BCAX: Multiplikator P/S|Rega marang dodolan personalis.com (PSNL)|Rasio rega marang pendapatan Erasca|Rasio kapitalisasi marang pendapatan DCTH (Delcath Systems Inc)|Kapitalisasi marang pendapatan YMAB (YmAbs)|Kapitalisasi marang volume dodolan AURA|Multiplikator P/S CADL (Candel Therapeutics, Inc.)|Multiplikator P/S accuray.com ARAY|SELLAS Life Sciences Group Inc. - Multiplikator P/S|Multiplikator rega marang pendapatan Actuate Therapeutics Inc. (ACTU)|CTOR: Multiplikator P/S|Rega marang dodolan TuHURA Biosciences (HURA)|Kapitalisasi marang pendapatan TARA|FATE: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Aadi Bioscience Inc (WHWK)|TCRX: Rasio rega marang dodolan|Multiplikator P/S CSBR (Champions Oncology, Inc.)|Rasio kapitalisasi pasar marang pendapatan XBIT|CEL-SCI Corp - Multiplikator P/S|OSTX - Multiplikator P/S|Radiopharm Theranostics (RADX) - Rasio rega marang pendapatan|Artiva Biotherapeutics - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Adlai Nortye Ltd|Kapitalisasi marang pendapatan Veru Corporation (VERU)|Multiplikator P/S TPST|Multiplikator P/S xiliotx.com (XLO)|Renovaro - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MURA|Kairos Pharma Inc - Multiplikator P/S|Multiplikator rega marang pendapatan OnKure Therapeutics Inc (OKUR)|w2.cytomed.sg (GDTC) - Rasio rega marang pendapatan|Curis - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Apollomics Inc.|Rega marang dodolan Tharimmune Inc THAR|Kapitalisasi marang pendapatan ADVB (Advanced Biomed Inc)|Multiplikator P/S Genprex Inc (GNPX)|Rasio rega marang pendapatan Calidi Biotherapeutics, Inc. CLDI|SBFM (sunshinebiopharma.com) - Rasio rega marang dodolan|Xenetic Bio - Multiplikator P/S|SLRX - Multiplikator P/S|PPBT: Multiplikator P/S|American Oncology Network, Inc. (AONC) - Multiplikator P/S|Rasio rega marang pendapatan BeiGene, Ltd.|checkpointtx.com - Rasio rega marang dodolan|Multiplikator P/S ELEV|icadmed.com (ICAD) - Multiplikator rega marang pendapatan|Multiplikator P/S IKNA (Ikena Oncology)|NTBL - Kapitalisasi marang pendapatan|Viracta - Multiplikator P/S|MOR - Multiplikator P/S|NAYA Biosciences Inc. (NAYA) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan AAPGV
